Enrichment of total serum IgG4 in patients with pemphigus

British Journal of Dermatology

Volumn 167, Issue 6, 2012, Pages 1245-1253

  Funakoshi, T ^a   Lunardon, L ^a   Ellebrecht, C T ^a   Nagler, A R ^a   O'Leary, C E ^a   Payne, A S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

ADULT; ARTICLE; CONTROLLED STUDY; DISSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; KERATINOCYTE; PATHOGENICITY; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROTEIN DEPLETION;

AUTOANTIBODIES; CASE-CONTROL STUDIES; DESMOGLEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MIDDLE AGED; PEMPHIGUS;

EID: 84870239167     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11144.x     Document Type: Article

References (36)

1. Payne AS, Stanley JR,. Pemphigus. In: Dermatology in General Medicine (, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds), 8th edn. New York: McGraw Hill, 2012.
2. Mahoney MG, Wang Z, Rothenberger K, et al. Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103: 461-8.
3. Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90: 919-26.
4. Amagai M, Hashimoto T, Shimizu N, et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
5. Amagai M, Hashimoto T, Green KJ, et al. Antigen-specific immunoabsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995; 104: 895-901.
6. Ding X, Diaz LA, Fairley JA, et al. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 1999; 112: 739-43.
7. Cheng SW, Kobayashi M, Tanikawa A, et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147: 261-5.
8. Rock B, Labib RS, Diaz LA,. Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest 1990; 85: 296-9.
9. Mascaro JM Jr, España A, Liu Z, et al. Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence. Clin Immunol Immunopathol 1997; 85: 90-6.
10. Payne AS, Ishii K, Kacir S, et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005; 115: 888-99.
11. Ishii K, Lin CY, Siegel DL, et al. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 2008; 128: 939-48.
12. Bhol K, Natarajan K, Nagarwalla N, et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 1995; 92: 5239-43.
13. Rock B, Martins CR, Theofilopoulos AN, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320: 1463-9.
14. Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desfmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000; 143: 337-42.
15. Warren SJ, Arteaga LA, Rivitti EA, et al. The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J Invest Dermatol 2003; 120: 104-8.
16. Futei Y, Amagai M, Ishii K, et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci 2001; 26: 55-61.
17. Torzecka JD, Wozniak K, Kowalewski C, et al. Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development? Arch Dermatol Res 2007; 299: 239-43.
18. Qaqish BF, Prisayanh P, Qian Y, et al. Development of an IgG4-based predictor of endemic pemphigus foliaceus (fogo selvagem). J Invest Dermatol 2008; 129: 110-18.
19. Aalberse RC, van der Gaag R, van Leeuwen J,. Serologic aspects of IgG4 antibodies. 1. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983; 130: 722-6.
20. Payne AS, Siegel DL, Stanley JR,. Targeting pemphigus autoantibodies by their heavy chain variable region genes. J Invest Dermatol 2007; 127: 1681-91.
21. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-17.
22. Ishii K, Harada R, Matsuo I, et al. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris. J Invest Dermatol 2005; 124: 939-46.
23. McHeyzer-Williams LJ, McHeyzer-Williams MG,. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
24. Zhang K, Mills FC, Saxon A,. Switch circles from Il-4-directed epsilon-class switching from human B-lymphocytes-evidence for direct, sequential, and multiple step sequential switch from mu to epsilon Ig heavy-chain gene. J Immunol 1994; 152: 3427-35.
25. Jeannin P, Lecoanet S, Delneste Y, et al. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160: 3555-61.
26. Hertl M, Eming R, Veldman C,. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116: 1159-66.
27. Takahashi H, Amagai M, Tanikawa A, et al. T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J Invest Dermatol 2006; 127: 324-30.
28. Dopp R, Schmidt E, Chimanovitch I, et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577-83.
29. Laffitte E, Skaria M, Jaunin F, et al. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br J Dermatol 2001; 144: 760-8.
30. Bernard P, Prost C, Aucouturier P, et al. The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita. J Invest Dermatol 1991; 97: 259-63.
31. Ferrari SE, Mudde GC, Rieger M, et al. IgG subclass distribution of antibodies against ADAMTS13 in patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 1703-10.
32. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-8.
33. Yamamoto M, Ohara M, Suzuki C, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz's disease. Scand J Rheumatol 2004; 33: 432-3.
34. Mao X, Payne AS,. Seeking approval: present and future therapies for pemphigus vulgaris. Curr Opin Invest Drugs 2008; 9: 497-504.
35. Plebani A, Ugazio AG, Avanzini MA, et al. Serum IgG subclass concentrations in healthy subjects at different age: age normal percentile charts. Eur J Pediatr 1989; 149: 164-7.
36. Moss RB, Carmack MA, Esrig S,. Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. J Pediatr 1992; 120: 16-21.